Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Actavis Completes Purchase of Serbia’s Zdravlje for $9.2 Million

April 29 (Bloomberg) -- Actavis Inc., the world’s fourth biggest maker of generic drugs, bought the entire equity of Serbia’s FHI Zdravlje AD as small shareholders sold their stock.

Actavis started the buyout on Nov. 2 to acquire 26.7 percent of the company it didn’t own and completed it at the cost of more than 7 million euros ($9.2 million), the company said in an e-mailed statement today.

Leskovac, Serbia-based Zdravlje was bought in 2002 for 3.5 million euros. Actavis said it invested more than 50 million euros in the plant, including the buyout.

To contact the reporter on this story: Misha Savic in Belgrade at

To contact the editor responsible for this story: James M. Gomez at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.